NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Shalby Limited reported a strong Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹295.5 crores and EBITDA rising 43.1% to ₹37.4 crores. The company achieved a significant turnaround in profitability, posting a PAT of ₹18.5 crores compared to a loss of ₹12.2 crores in the previous year, aided by a transition to a new tax regime. The MedTech (implant) business showed robust growth, with annual revenue crossing ₹135 crores and turning EBITDA positive at ₹6.7 crores for the full year. Despite geopolitical headwinds affecting the Gurugram unit's international patient flow, overall operational metrics like ARPOB and occupancy remained stable.
முக்கிய அம்சங்கள்
Consolidated EBITDA grew by 43.1% YoY to ₹37.4 crores in Q4 FY26, with margins expanding to 12.7%.Shalby MedTech revenue increased by 46% in FY26 to ₹135 crores, achieving a full-year positive EBITDA of ₹6.7 crores.Standalone ARPOB improved by 2.7% to ₹42,689, while group-level occupancy stood at 48% (50% excluding the Gurugram unit).The company successfully completed 70 transplants, including 51 kidney and 19 liver transplants, during FY26.Maintained a healthy balance sheet with a gearing ratio of 0.44x and net debt of ₹446.2 crores.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful turnaround of the MedTech segment and the recurring tax benefits which are expected to sustain higher PAT margins. Monitor the recovery of international patient volumes at the Gurugram facility as geopolitical tensions ease.
Vaishali Pharma Approves Audited Q4 and FY26 Financial Results
The Board of Directors of Vaishali Pharma Limited met on May 30, 2026, to approve the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The meeting was held late in the evening, concluding at 10:50 P.M. This announcement confirms the completion of the annual audit process in compliance with SEBI regulations. While specific financial figures were not detailed in the cover letter, the approval marks the formal release of the company's performance data for the 2025-26 fiscal year.
முக்கிய அம்சங்கள்
Board approved Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026.The meeting was conducted on May 30, 2026, starting at 10:00 P.M. and ending at 10:50 P.M.The submission includes the Audit Report for both the fourth quarter and the full financial year.Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables in the attached Annexure I to assess revenue growth and margin stability. Compare the full-year FY26 performance against FY25 to determine the company's growth trajectory.
Shalimar Paints CFO Sachin Naik Resigns Effective May 30, 2026
Mr. Sachin Naik has resigned from his position as the Chief Financial Officer (CFO) and Key Managerial Personnel of Shalimar Paints Limited. The resignation is effective from the close of business hours on May 30, 2026. The company stated the reason for his departure is to pursue better career opportunities and professional growth prospects. No immediate successor was announced in the filing.
முக்கிய அம்சங்கள்
Mr. Sachin Naik resigned as Chief Financial Officer (CFO) effective May 30, 2026.The resignation is categorized as a change in Key Managerial Personnel (KMP) under SEBI regulations.The stated reason for resignation is better career opportunities and professional growth.The disclosure was filed in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements for the appointment of a new CFO to ensure leadership continuity and stability in financial management.
Shah Alloys FY26 Results: Massive Exceptional Gains of ₹9,000+ Lakhs Amidst Plant Closure
Shah Alloys Limited reported its FY26 results, heavily influenced by one-time exceptional gains from asset liquidations and debt settlements. While the company recorded significant gains including ₹5,347.68 lakhs from plant sales and ₹1,398.41 lakhs from SAL Steel disinvestment, its core Iron and Steel plant has been shut down since August 2025. Auditors have issued a 'Material Uncertainty Related to Going Concern' warning due to the cessation of operations and persistent losses. The company also settled HDFC Bank dues of ₹2,523.77 lakhs for a reduced payment of ₹1,800 lakhs.
முக்கிய அம்சங்கள்
Recognized an exceptional gain of ₹5,347.68 lakhs from the sale of plant, machinery, and technical know-how.Settled HDFC Bank liabilities of ₹2,523.77 lakhs for ₹1,800 lakhs, resulting in a ₹723.77 lakhs waiver.Auditors raised 'Material Uncertainty' regarding the company's ability to continue as a going concern following the August 2025 plant shutdown.Booked a profit of ₹1,691.53 lakhs from the sale of its 16-inch Rolling Mill Plant for ₹1,700 lakhs.Realized a gain of ₹1,398.41 lakhs through the disinvestment of shares in associate company SAL Steel Limited.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the reported profits are driven by asset sales rather than core business operations, which have effectively ceased. The auditor's 'going concern' warning is a major red flag indicating the company's future viability is at risk.
Shalimar Paints Reports First Positive EBITDA Since Acquisition in FY26 Results
Shalimar Paints has achieved a significant operational milestone by reporting positive EBITDA for the full year FY 2025-26, the first since its acquisition by Hella Infra Market Limited. The company successfully implemented cost rationalization measures, specifically reducing employee and manufacturing expenses to improve operating leverage. A strategic shift towards premiumization, particularly in high-margin emulsion products, has enhanced the overall margin profile. Despite industry-wide pricing pressures and volatile demand, the management indicates a successful business turnaround and a strengthened foundation for sustainable growth.
முக்கிய அம்சங்கள்
Delivered positive EBITDA for the first time since the majority stake acquisition by Hella Infra Market Limited.Executed focused cost rationalization leading to significant reductions in employee, manufacturing, and operating expenses.Improved product mix through premiumization and increased saliency of high-margin emulsion products.Statutory auditors Walker Chandiok & Co., LLP issued an unmodified opinion on the audited financial results.Strengthened business fundamentals and operational efficiencies despite persistent sector-wide headwinds.
👀 கவனிக்க வேண்டியவை
Investors should view the positive EBITDA as a critical turnaround signal and monitor if this leads to consistent net profitability. Watch for the company's ability to maintain market share against larger competitors while sustaining these improved margins.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Halder Venture Limited has approved its audited financial results for the fiscal year ended March 31, 2026. A major highlight is the board's proposal to increase the company's borrowing limits and investment/loan limits to ₹1,000 crores each, pending shareholder approval. The company is also undergoing a statutory auditor transition, proposing P. Somani & Co. for a five-year term as the current auditor's tenure concludes. These structural and financial limit changes suggest the company is positioning itself for significant capital deployment or expansion.
முக்கிய அம்சங்கள்
Approved standalone and consolidated audited financial results for the quarter and year ended March 31, 2026.Proposed a significant increase in borrowing limits up to ₹1,000 crores under Section 180(1)(c).Proposed increasing limits for providing loans, guarantees, and investments up to ₹1,000 crores under Section 186.Recommended the appointment of M/s P. Somani & Co. as Statutory Auditors for a 5-year term starting from the 44th AGM.Reappointed J Kumar Jain & Associates as Internal Auditors and J Pal & Co as Cost Auditors for FY 2026-27.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the specific reasons for the massive hike in borrowing limits to ₹1,000 crores, as this may precede a major acquisition or expansion phase. It is also essential to review the full audited financial report to evaluate the company's current debt-to-equity ratio before these new limits are utilized.
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has appointed new Cost and Secretarial Auditors to maintain statutory compliance. The Interim Resolution Professional (IRP) has taken on record a backlog of financial results, including consolidated results for three quarters of 2025 and audited standalone results for the full year ended March 31, 2026. Although the CIRP process is currently stayed by the NCLAT pending settlement discussions, the IRP remains in control of management. These actions are necessary steps to keep the company's regulatory filings current during its legal restructuring.
முக்கிய அம்சங்கள்
M/s Amit Gupta & Associates appointed as Secretarial Auditor for a 5-year term (FY 2025-26 to 2029-30).M/s Cheena & Associates appointed as Cost Auditor for Sugar and Distillery units for FY 2025-26.Audited standalone financial results for the year ended March 31, 2026, were approved and taken on record.Company has been under CIRP since July 11, 2024, with the Board of Directors currently suspended.NCLAT has reserved judgment on the CIRP stay as of May 13, 2026, following settlement discussions with creditors.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the company is in insolvency; the key trigger to watch is the NCLAT's final judgment on the CIRP stay and the outcome of creditor settlements.
Simbhaoli Sugars, currently under the Corporate Insolvency Resolution Process (CIRP), has released multiple quarters of delayed financial results and appointed new auditors. The company's board remains suspended, with the Interim Resolution Professional (IRP) managing operations under a stay order from the NCLAT. Notably, the statutory auditors have issued an adverse opinion on the consolidated results for the quarter ended June 30, 2025. This indicates significant concerns regarding the company's financial reporting and its ability to continue as a going concern amidst ongoing legal and insolvency proceedings.
முக்கிய அம்சங்கள்
Company is undergoing CIRP since July 11, 2024, with board powers suspended and managed by an IRP.Auditors issued an 'Adverse Opinion' on the consolidated financial results for the quarter ended June 30, 2025.Delayed financial results for Q1, Q2, Q3 of FY2025 and Audited Standalone results for FY2026 were taken on record.M/s Amit Gupta & Associates appointed as Secretarial Auditor for a 5-year term starting FY 2025-26.NCLAT has reserved judgment on the CIRP matter as of May 13, 2026, following settlement discussions among creditors.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings and has received an adverse auditor opinion. The stock remains highly speculative until the NCLAT judgment is pronounced and a clear resolution plan or settlement is finalized.
Haleos Labs Limited has recommended a final dividend of Rs 1.50 (15%) per equity share for FY2025-26. The company's annual standalone revenue declined to Rs 300.99 crore from Rs 333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to Rs 17.78 crore from Rs 21.37 crore. Alongside results, the company announced the resignation of an independent director and the reappointment of a Whole-time Director for five years.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 1.50 per equity share of Rs 10 face value.Annual standalone revenue decreased by 9.7% YoY to Rs 30,098.96 Lakhs.Standalone Net Profit for FY26 fell to Rs 1,777.68 Lakhs compared to Rs 2,137.08 Lakhs in FY25.Q4 FY26 revenue dropped significantly to Rs 6,338.42 Lakhs from Rs 8,542.78 Lakhs in the year-ago quarter.Earnings Per Share (EPS) for the full year decreased to Rs 58.80 from Rs 70.69.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the dividend payout comes amid declining revenue and profitability. Monitor the company's ability to arrest the top-line slide and the impact of the upcoming statutory auditor change.
Halder Venture Revises Valuation Report for Preferential Issue of 7.93 Lakh Warrants
Halder Venture Limited has submitted a revised valuation report for its proposed preferential issue of 7,93,650 convertible warrants. The revision was triggered by observations from the NSE and BSE, which classified the company's equity shares as "frequently traded shares." This classification requires a valuation update in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The update ensures regulatory compliance for the capital raising process initiated on May 13, 2026.
முக்கிய அம்சங்கள்
Proposed preferential issue involves 7,93,650 Convertible Warrants.Revision follows NSE and BSE classification of shares as 'frequently traded'.Valuation updated to comply with Chapter V of SEBI ICDR Regulations.The company has uploaded the full revised valuation report to its official website for transparency.
👀 கவனிக்க வேண்டியவை
Investors should check the revised valuation report on the company's website to see if the warrant pricing has changed. Monitor for further updates on the final allotment and the intended use of the raised capital.
Shalby Q4 FY26 Consolidated PAT Surges 251% YoY to ₹185 Mn; EBITDA Up 43%
Shalby Limited reported a robust Q4 FY26 with consolidated revenue growing 9.4% YoY to ₹2,955 mn. The company achieved a significant 43.1% YoY growth in consolidated EBITDA to ₹374 mn, while PAT reached ₹185 mn, largely supported by the transition to a new tax regime. Operational metrics in the hospital business showed improvement with occupancy rising to 48% from 45% YoY, although surgery counts dipped by 6.7%. The MedTech segment continues to diversify the revenue stream, contributing 13.5% to the total quarterly turnover.
முக்கிய அம்சங்கள்
Consolidated Q4 FY26 Revenue increased 9.4% YoY to ₹2,955 mn; Full-year FY26 revenue stood at ₹11,682 mn.Consolidated EBITDA for Q4 FY26 rose 43.1% YoY to ₹374 mn, with margins improving to 12.7% from 9.7% YoY.Hospital occupancy rate improved to 48% in Q4 FY26 vs 45% in Q4 FY25, while ARPOB grew 2.7% to ₹42,689.Shalby MedTech (Implant business) generated ₹400.4 mn in revenue during the quarter, accounting for 13.55% of consolidated revenue.Consolidated Net Debt as of March 31, 2026, stood at ₹4,462 mn with an annualized ROCE of 7.3%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to scale the high-margin MedTech business and the turnaround of the Shalby International (Delhi-NCR) unit, which is currently EBITDA negative. The core hospital business remains a steady cash generator with improving occupancy levels.
Shalby Ltd FY26 Standalone Revenue Grows to ₹8,986 Million; No Dividend Recommended
Shalby Limited reported a steady growth in its standalone operations for the financial year ended March 31, 2026, with revenue from operations reaching ₹8,985.58 million compared to ₹8,688.60 million in FY25. The fourth quarter (Q4 FY26) saw revenue of ₹2,248.54 million, reflecting a 5.3% sequential growth from Q3 FY26. Despite the revenue growth, the Board has opted not to recommend any dividend for the financial year 2025-26. Additionally, the company has appointed M/s. Borad Sanjay B & Associates as Cost Auditors for the upcoming fiscal year.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations for FY26 rose to ₹8,985.58 million from ₹8,688.60 million in the previous year.Q4 FY26 Revenue stood at ₹2,248.54 million, up from ₹2,135.09 million in Q3 FY26 and ₹2,070.03 million in Q4 FY25.Total Standalone Income for the full year FY26 reached ₹9,234.15 million.The Board of Directors did not recommend any dividend for the financial year 2025-26.The 22nd Annual General Meeting (AGM) of the company is scheduled for September 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should review the full consolidated financial statements to assess overall group profitability and margin trends. The decision to skip dividends suggests the company may be prioritizing capital conservation or reinvestment into operations.
Kaushalya Infrastructure Development Corporation has approved its audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. The independent auditor's report confirms a true and fair view of the company's financial position with an unmodified opinion, suggesting no major accounting discrepancies. While the specific numerical data for revenue and profit were not detailed in the cover letter, the auditors confirmed compliance with Ind AS and statutory requirements. The company also stated there were no material foreseeable losses on long-term contracts.
முக்கிய அம்சங்கள்
Board approved audited standalone and consolidated financial results for the full year ended March 31, 2026.Statutory auditors K A S G & CO. issued an unmodified opinion on the financial statements.The company confirmed no amounts were required to be transferred to the Investor Education and Protection Fund.Managerial remuneration for FY26 was paid in accordance with Section 197 of the Companies Act, 2013.Management represented that no funds were advanced or loaned to intermediaries for undisclosed investments.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables and profit/loss statements once fully published to assess the company's operational performance, as the auditor's report only confirms accounting integrity.
Chalet Hotels Wins Favorable Supreme Court Ruling on Navi Mumbai Hotel Land Dispute
The Supreme Court has ruled in favor of Chalet Hotels regarding the land allotment for its Four Points by Sheraton Navi Mumbai property. The court set aside a previous Bombay High Court order that mandated the return of the land to CIDCO and the restoration of the plot to its original state. Instead, the SC has allowed for the regularization of the land allotment, contingent upon the payment of specific amounts. This ruling removes a significant operational risk for the company, securing a key asset that was previously under threat of closure.
முக்கிய அம்சங்கள்
Supreme Court sets aside Bombay HC order for restoration of Navi Mumbai hotel land to CIDCO.The ruling pertains to the Four Points by Sheraton Navi Mumbai, Vashi, a key operating asset for the company.SC upholds a mechanism for regularization of the land allotment instead of eviction or demolition.Regularization is subject to payment of amounts as determined by the Supreme Court judgment.The company is currently evaluating the detailed judgment to determine the exact financial implications of the payment.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major de-risking event that secures the future of a key operating asset. Monitor upcoming disclosures for the specific financial impact of the regularization fees to assess any short-term cash flow implications.
Vaishali Pharma Re-appoints MD Atul Vasani and Two Directors for 5-Year Terms
Vaishali Pharma Limited has announced the re-appointment of its core leadership team for five-year terms during its board meeting on May 23, 2026. Mr. Atul Arvind Vasani, the promoter and chairman with over 30 years of industry experience, has been re-appointed as Managing Director until May 2031. Mrs. Jagruti Vasani continues as Whole-Time Director, while Mr. Pratik Vikram Jakhelia has been re-appointed as an Independent Director for a second term. These leadership extensions, subject to shareholder approval, ensure management continuity and stability for the company's long-term operations.
முக்கிய அம்சங்கள்
Mr. Atul Arvind Vasani re-appointed as Managing Director for a 5-year term ending May 22, 2031Mrs. Jagruti Vasani re-appointed as Whole-Time Director for 5 years, bringing 15+ years of experienceMr. Pratik Vikram Jakhelia re-appointed as Independent Director for a 2nd term of 5 years starting Sept 2026The leadership team includes the promoter who has been in the pharmaceutical industry since 1987All re-appointments are subject to the final approval of the company's members
👀 கவனிக்க வேண்டியவை
This announcement confirms management continuity, which is a positive sign for long-term stability. Investors should monitor the company's performance under this established leadership.
Haleos Labs Credit Rating Reaffirmed at IVR BBB/Positive; Rated Facilities Enhanced to ₹116 Cr
Infomerics Valuation and Rating Limited has reaffirmed the credit ratings for Haleos Labs Limited and its material subsidiary, Mahi Drugs Private Limited. The company's long-term rating is maintained at IVR BBB with a 'Positive' outlook, while the short-term rating remains IVR A3+. Significantly, the total rated bank loan facilities for the parent company have been enhanced from ₹81.86 crore to ₹116.01 crore, indicating increased borrowing capacity for operations or expansion.
முக்கிய அம்சங்கள்
Long-term rating reaffirmed at IVR BBB with a 'Positive' outlook for Haleos Labs Limited.Short-term rating reaffirmed at IVR A3+ for fund-based and non-fund based bank facilities.Total rated bank loan facilities for the company increased from ₹81.86 crore to ₹116.01 crore.Material subsidiary Mahi Drugs Private Limited's rated facilities enhanced to ₹20.75 crore with IVR BB+/Stable rating.Ratings assessment included operational and financial performance data up to 9MFY26.
👀 கவனிக்க வேண்டியவை
The 'Positive' outlook indicates a potential for a rating upgrade in the medium term if financial performance stays robust. Investors should monitor the company's ability to service the increased debt levels as it utilizes the enhanced bank facilities.
HAL Q4FY26: Revenue Up 7% to ₹33,050 Cr; Order Book Hits Record ₹2.54 Lakh Cr
HAL reported a 7% YoY revenue growth to ₹33,050 crores for FY26, with EBITDA margins remaining robust at 30%. The company's order book has reached a significant milestone of ₹2,54,538 crores, supported by ₹97,028 crores in fresh orders during the year. Management expects double-digit revenue growth in FY27 and anticipates starting LCA Mark-1A deliveries by August-September 2026. A massive ₹12,000 crore capex plan is set through 2030 to ramp up production for LCA, LCH, and engine projects.
முக்கிய அம்சங்கள்
Revenue from operations grew 7% YoY to ₹33,050 crores; EBITDA increased 11% to ₹13,472 crores.Order book stands at a record ₹2,54,538 crores with an additional pipeline of ₹90,000 crores expected over the next 2 years.LCA Mark-1A deliveries are now targeted for August-September 2026 following the receipt of 6 GE engines.Company plans to invest ₹12,000 crores in capex by 2030 to expand manufacturing infrastructure for LCA Mark-II and GE 414 engines.R&D expenditure remained high at ₹2,794 crores, representing 8.4% of total revenue for FY26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the commencement of LCA Mark-1A deliveries in Q2FY27 as a key execution milestone. The record-high order book provides multi-year revenue visibility, supporting a positive long-term outlook despite short-term supply chain delays.
Chalet Hotels FY26 Revenue Jumps 60% to ₹28.1 Bn; PAT Surges 353% on Strong Growth
Chalet Hotels delivered a robust FY26 performance with consolidated revenue growing 60% YoY to ₹28,124 million, significantly aided by the residential segment. The core hospitality business maintained momentum with a 13.5% increase in ADR to ₹13,727, while the commercial real estate segment saw a 55% revenue jump. Net profit witnessed a massive 353% surge to ₹6,450 million. The company is aggressively expanding its footprint, crossing the 5,000-key milestone with new luxury projects in Hyderabad and Udaipur.
முக்கிய அம்சங்கள்
Consolidated FY26 Revenue grew 60% YoY to ₹28,124 mn; EBITDA (Ex-Residential) rose 21% to ₹9,573 mn.Hospitality ADR increased 13.5% to ₹13,727 for the full year, despite a slight Q4 RevPAR dip of 3% due to geopolitical factors.Portfolio expanded to 5,000+ keys including a new 330-key Ritz Carlton in Hyderabad and a 144-key resort acquisition in Udaipur.Commercial Real Estate revenue grew 55% YoY to ₹3,061 mn with a high EBITDA margin of 83.1%.Residential project contributed ₹7,383 mn to revenue in FY26 with 152 units handed over.
👀 கவனிக்க வேண்டியவை
Investors should remain positive on Chalet Hotels given its successful diversification into high-margin commercial and residential segments alongside core hospitality. The aggressive expansion into luxury and leisure markets provides a strong visibility for future earnings growth.
Chalet Hotels FY26 Revenue Up 18% to ₹20.7 Bn; Announces Entry into Udaipur and Hyderabad
Chalet Hotels reported a robust FY26 with consolidated revenue (ex-residential) growing 18% YoY to ₹20,741 million and EBITDA rising 21% to ₹9,573 million. The hospitality segment achieved a strong ADR growth of 13.5% YoY to ₹13,727, although RevPAR growth was limited to 5.1% due to occupancy declines in specific micro-markets. The company significantly expanded its footprint by acquiring a 144-key resort in Udaipur for ₹1,710 million and announcing a new 330-key Ritz Carlton in Hyderabad. The residential segment also saw major revenue recognition of ₹7,383 million following unit handovers.
முக்கிய அம்சங்கள்
FY26 Consolidated Revenue (ex-residential) grew 18% YoY to ₹20,741 mn with EBITDA margins at 46.2%Hospitality ADR increased 13.5% YoY to ₹13,727 for FY26, with Q4 ADR reaching ₹15,456Acquired Inder Residency in Udaipur for ₹1,710 mn and announced a ₹5,610 mn Ritz Carlton project in HyderabadCommercial Real Estate revenue surged 55% YoY to ₹3,061 mn with a high EBITDA margin of 83.1%Residential project recognized ₹7,383 mn in revenue for FY26 with 152 units handed over
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition toward brand ownership and its aggressive expansion into high-yield leisure and luxury segments. The strong ADR growth and healthy margins in the commercial segment provide a solid foundation for long-term capital appreciation.
Chalet Hotels has recommended a final dividend of Re. 1 per share (10% of face value) for the financial year ended March 31, 2026. The company is also seeking shareholder approval to raise up to Rs. 10,000 million through debt instruments like NCDs and Commercial Paper to support its capital structure. Additionally, the board approved a 30% stake dilution in its subsidiary, Chalet Airport Hotel Private Limited, where it will retain a 70% majority stake. Progress was also noted regarding the Vashi hotel litigation, with CIDCO approving regularization subject to differential premium payments.
முக்கிய அம்சங்கள்
Recommended a final dividend of Re. 1 per equity share (10% of face value) for FY26.Proposed fundraise of up to Rs. 10,000 million (Rs. 1,000 crore) via NCDs or Commercial Paper.Approved 30% stake dilution in Chalet Airport Hotel Private Limited, retaining 70% ownership.Total investment in the Airport Hotel subsidiary is Rs. 385 crore comprising debt and equity.CIDCO approved regularization of Vashi hotel land allotment, potentially resolving a long-standing legal dispute.
👀 கவனிக்க வேண்டியவை
Investors should take note of the dividend payout and the significant fundraise plan which signals growth and refinancing intent. The potential resolution of the Vashi land litigation is a significant positive development that could remove a long-term legal overhang on the stock.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
